Genetic alterations as diagnostic markers in digestive tract cancer;Interet physiopathologique et diagnostique des alterations genetiques des cancers digestifs

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 5 BIS, 1996, Pages

  Laurent Puig, Pierre ^a,b   Fléjou, Jean François ^c  

^a INSTITUT CURIE   (France)

^b BICÊTRE HOSPITAL   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Aberrant crypt; Colorectal neoplasm; K ras; Mutation; Pancreatic cancer

Indexed keywords

RAS PROTEIN;

COLORECTAL CANCER; CONFERENCE PAPER; CRYPT CELL; DIGESTIVE SYSTEM CANCER; GENE MUTATION; HUMAN; MARKER GENE; ONCOGENE K RAS; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; ANIMAL; DIGESTIVE SYSTEM TUMOR; GENETIC MARKER; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; REVIEW;

ANIMALS; DIGESTIVE SYSTEM NEOPLASMS; GENES, RAS; GENETIC MARKERS; HUMANS; MUTATION; RAS PROTEINS;

EID: 0029743154     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215-21.
2. Feraon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987;238:193-6.
3. Bishop J. The molecular genetics of cancer. Science 1987;235:305-11.
4. Satoh T, Kaziro Y. Ras signal transduction. Semin Cancer Biol 1992;3:169-77.
5. Satoh T, Nakafuku M, Kaziro Y. Function of ras as a molecular switch in signal transduction. J Biol Chem 1992;267:24149-52.
6. Hall A. The cellular functions of small GTP-binding proteins. Science 1990;249:635-40.
7. Feig LA. The many roads that leads to Ras. Science 1993;260:767-80.
8. Bollag G, McCormick F. Regulators and effectors of ras proteins. Annu Rev Cell Biol 1993;7:601-32.
9. McCormick F. How receptors turn Ras on. Nature 1993;363:15-6.
10. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
11. Marshall CJ. How does p21ras transform cells. Trends Genet 1991;7:91-5.
12. Tong L, De Vos AM, Milburn MV, Jancarik J, Noguchi S, Nishimura S, et al. Structural differences between a ras oncogene protein and the normal protein. Nature 1989;337:90-3.
13. Grunewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
14. Smit VTHBM, Boot AMM, Fleuren GF, Cornelisse CJ, Bos JL. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma. Nucleic Acids Res 1988;16:7773-82.
15. Fujita K, Ohuchi N, Yao T, Okamura M, Fukashima Y, Kanakura Y, et al. Frequent overexpression, but not activation by point mutation of ras gene in primary human gastric cancers. Gastroenterology 1987;93:1339-45.
16. Haas M, Isakov J, Howell SB. Evidence against ras activation in human ovarian carcinomas. Mol Biol Med 1987;4:265-75.
17. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988;48:4459-63.
18. Ahuja HG, Foti A, Bareli M, Cline MJ. The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990;75:1684-90.
19. Nagata Y, Abe M, Kobayachi K, Saiki S, Kotake T, Yoshikawa Y, et al. Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn J Cancer Res 1990;81:22-7.
20. Rodenhuis S. Ras and human cancer. Cancer Res 1992;52:2665-9.
21. Ming SC. Dysplasia of gastric epithelium. Front Gastrointest Res 1979;4:164-72.
22. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggit RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-66.
23. Pascal RR. Consistency in a terminology of colorectal dysplasia. Hum Pathol 1988;19:1242-50.
24. Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989;20:1008-14.
25. Dixon MF, Brown LJR, Gilmour HM, Price AB, Smeeton NC, Talbot IC, et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988;13:385-97.
26. Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N, et al. Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 1991;6:1079-83.
27. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
28. Hasegawa Y, Takeda S, Ichii S, Koizumi K, Maruyama M, Fujii A, et al. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 1995;10:1441-5.
29. Tobi M, Luo FC, Ronai Z. Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J Natl Cancer Inst 1994;86:1007-10.
30. Minamoto T, Yamashita N, Ochiai A, Mai M, Sugimura T, Ronai Z, et al. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer 1995;75:1520-6.
31. Ronai Z, Luo FC, Gradia S, Hart WJ, Butler R. Detection of K-ras mutation in normal and malignant colonic tissues by an enriched PCR method. Int J Oncol 1994;4:391-6.
32. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991;51:1564-7.
33. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
34. Roncucci L, Pedroni M, Fante R, Di Gregorio C, Ponz de Leon M. Cell kinetic evaluation of human colonic aberrant crypts. Cancer Res 1993;53:3726-9.
35. Yamashita N, Minamoto T, Onda M, Esumi H. Increased cell proliferation of azoxymethane-induced aberrant crypt foci of rat colon. Jpn J Cancer Res 1994;85:692-8.
36. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994;54:5527-30.
37. Pretlow TP, Brasitus TA, Fulton NC, CheyerC, Kaplan EL. K-ras mutations in putative preneoplastic lesions in human colon, J Natl Cancer Inst 1993;85:2004-7.
38. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;54:5523-6.
39. Bedenne L, Faivre J, Boutron MC, Piard F, Cauvin JM, Hillon P. Adenoma-carcinoma sequence or de novo carcinogenesis? A study of adenomatous remnants in a population based series of large bowel cancer. Cancer 1992;69:883-8.
40. Shimoda T, Ikegami M, Fujisaki J, Matsui T, Aizawa S, Ishikawa E. Early colorectal carcinoma with special reference to its development de novo. Cancer 1989;64:1138-46.
41. Laurent-Puig P, Olschwang S, Delattre O, Validire P, Melot T, Mosseri V, et al. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. Int J Cancer 1991;49:220-3.
42. Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, Esumi H. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994;54:2841-4.
43. Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K, Maeda S. Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int J Cancer 1994;57:51-5.
44. Hasegawa H, Ueda M, Watanabe M, Teramoto T, Mukai M, Kitajima M. K-ras gene mutations in early colorectal cancer. Flat elevated vs polyp-forming cancer. Oncogene 1995;10:1413-6.
45. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-32.
46. Ando M, Maruyama M, Oto M, Takemura K, Endo M, Yuasa Y. Higher frequency of point mutations in the c-Ki-ras gene in human colorectal adenoma with severe atypia than carcinoma. Jpn J Cancer Res 1991;82:245-9.
47. Hruban RH, Van Mansfeld AD, Offerhaus GJ, Van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
48. Tada M, Omata M, Ohto M. Ras genes mutations in intraductal papillary neoplasms of the pancreas. Analysis of five cases. Cancer 1991;7:634-7.
49. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
50. Warshaw AL, Fernandez del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
51. Ihalainen J, Taavitsainen M, Salmivaara T, Palotie A. Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing. J Clin Pathol 1994;47:1082-4.
52. Van Es JM, Polak MM, Van den Berg FM, Ramsoekh TB, Craanen ME, Hruban RH, et al. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 1995;48:218-22.
53. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM, et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990;50:1279-83.
54. Urban T, Ricci S, Grange JD, Lacave R, Boudghene F, Breittmayer F, et al. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993;85:2008-12.
55. Watanabe H, Sawabu N, Ohta H, Satomura Y, Yamakawa O, Motoo Y, et al. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res 1993;84:961-5.
56. Trumper LH, Burger B, Von Bonin F, Hintze A, Von Blohn G, Pfreundschuh M, et al. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer 1994;70:278-84.
57. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, el al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
58. Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991;100:233-8.
59. DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, Van den Berg FM, Cameron JL, et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-95.
60. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano T, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953-6.
61. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
62. Berthelemy P, Bouissou M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L. Identification of K-ras mutations in pancreatic juice in early diagnosis of pancreatic cancer. Ann Intern Med 1995;123:188-91.
63. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992;52:4507-13.